Semaglutide to Reduce Atrial Fibrillation Burden

A phase 4 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 132 participants.

Also called NCT05209165

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 132 participants (planned count) (from the registry)
Sponsor
San Francisco Veterans Affairs Medical Center (from the registry)
Registry
  • NCT NCT05209165
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Suspended (from the registry)

Technical summary

Registry record NCT05209165. Randomized; quadruple masking; primary purpose treatment. Start 2023-05 (anticipated); primary completion 2027-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Semaglutide to Reduce Atrial Fibrillation Burden
Condition
Obesity
Condition
Overweight
Intervention (Drug)
Semaglutide
Intervention (Drug)
Placebo
Lead sponsor
San Francisco Veterans Affairs Medical Center (class: US federal agency)

Record details

Record id
cardio:ct-nct05209165
Content hash
5cba25dc2172e9b12404776baaf0be7d1b863530a912e4fc36c0d1a778a2ebdb